

Thalomid® – Prior Authorization Request (For Maryland Only)

Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155

CVS/caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS/caremark toll-free at 866-249-6155.** If you have questions regarding the prior authorization, please contact CVS/caremark at **866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 800-237-2767.

Patient Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

1. What drug is being prescribed? Thalomid® Other _____
2. What is the prescribed dose per day? _____ mg/day
3. What is the patient's diagnosis?

<input type="checkbox"/> Erythema nodosum leprosum (ENL) <input type="checkbox"/> Systemic light chain amyloidosis <input type="checkbox"/> Behcet's syndrome <input type="checkbox"/> AIDS-related diarrhea <input type="checkbox"/> Waldenström's macroglobulinemia / lymphoplasmacytic lymphoma <input type="checkbox"/> Myeloma or progressive solitary plasmacytoma <input type="checkbox"/> <input type="checkbox"/> Other _____	<input type="checkbox"/> HIV-related aphthous ulcer of mouth or esophagus <input type="checkbox"/> Cancer-related cachexia <input type="checkbox"/> Chronic graft versus host disease <input type="checkbox"/> Myelofibrosis with myeloid metaplasia
--	---
4. What is the ICD code? _____
5. Would the prescriber like to request an override of the step therapy requirement? Yes No If no, skip to #8.
6. Has the member received the medication through a pharmacy or medical benefit within the past 180 days? Yes No
ACTION REQUIRED: Please provide documentation to substantiate the member had a prescription paid for within the past 180 days (i.e., PBM medication history, pharmacy receipt, EOB etc.)
7. Is the medication effective in treating the member's condition? Yes No
 Continue to #8 and complete this form in its entirety.
8. How will Thalomid® be used?

<input type="checkbox"/> Monotherapy / Single agent
<input type="checkbox"/> Dexamethasone
<input type="checkbox"/> Dexamethasone and cyclophosphamide
<input type="checkbox"/> Rituximab (Rituxan)
<input type="checkbox"/> Dexamethasone and bortezomib (Velcade)
<input type="checkbox"/> Melphalan and prednisone
<input type="checkbox"/> Dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide (DT-PACE)
<input type="checkbox"/> Other _____

Complete the following section based on patient's diagnosis

Section A: Multiple Myeloma

9. Is Thalomid being used as:
- Primary therapy
 - Maintenance therapy, no further questions
 - Salvage therapy, skip to #11
10. If being used as primary therapy, is the member eligible for stem cell transplant? Yes No *No further questions*
11. If being used as salvage therapy, will the Thalomid be used as part of the same chemotherapy regimen as their primary therapy? Yes No *If no, no further questions.*
12. Was the patient a transplant candidate? Yes No

Section B: Cachexia

13. Is the cachexia due to HIV infection or cancer? Yes No

Section C: Kaposi's Sarcoma

14. Does the patient have an HIV infection? Yes No

Section D: Graft-versus-Host Disease

15. Has the patient received a bone marrow transplant? Yes No
16. Is Thalomid being used as:
- Treatment of chronic or recurrent graft-versus-host disease
 - Prophylaxis of chronic or recurrent graft-versus-host disease
 - Other _____

17. Was the disease refractory to other therapies? Yes No

Section E: Crohn's Disease

18. Did the patient have a previous failure of, or intolerance to, standard therapies (e.g., corticosteroids, sulfasalazine [Azulfidine], azathioprine [Azasan, Imuran])? Yes No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS/caremark or the benefit plan sponsor.

X _____
Prescriber or Authorized Signature **Date: (mm/dd/yy)**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Thalomid SGM 4/2014